Event: Tuesday, August 4, 2026 — 2026 Q2 earnings call
Company: Henry Schein (NASDAQ: HSIC)
Henry Schein enters Q2 with a more constructive operating setup than it had a year ago: U.S. dental demand and share trends improved in Q1, technology remained a durable growth engine, and management reported early gross-margin benefits from its value-creation work. The central question for Q2 is whether those early gains are repeatable and broadening—especially given easier comparisons in dental distribution, a less favorable medical-testing backdrop, and the fact that much of the targeted cost savings are expected to arrive in the second half.
The report is therefore less about a one-quarter revenue beat than about confirming three elements of the 2026 earnings algorithm:
In Q1, HSIC generated $3.37 billion of sales, up 6.3% reported and 2.5% internally in local currency, while non-GAAP EPS rose 14.8% to $1.32. Adjusted EBITDA increased 11.6% to $289 million. Importantly, non-GAAP operating margin expanded 28 basis points year over year to 7.53%, supported by distribution and technology gross-margin improvement and business mix. (investor.henryschein.com)
The quality of the Q1 result was favorable in dental and technology:
One caveat: Q1 included an approximately $11 million remeasurement gain, or roughly $0.07 per diluted share, from taking control of S.I.N. 360. That gain was not excluded from reported non-GAAP EPS, so investors should assess Q2 profitability against an approximately $1.25 underlying Q1 EPS base, rather than mechanically annualizing $1.32.
The most important underlying sales signal is U.S. dental. In Q1, U.S. dental merchandise grew 4.1% internally and equipment grew 3.4% internally, with management attributing the strength to share gains, price, and stable-to-improving procedure activity. Management also highlighted DSO growth, healthy traditional-equipment demand, and a stable equipment backlog. (investor.henryschein.com)
This is particularly relevant against the Q2 2025 comparison, when U.S. dental merchandise fell 1.2% and U.S. dental equipment fell 4.7% amid lower glove prices, promotional activity, and tariff-related uncertainty. HSIC should face an easier year-over-year setup in Q2 2026, but investors will want to distinguish between:
Constructive outcome: sustained mid-single-digit U.S. dental organic growth, led by merchandise, traditional equipment, and corporate brands.
Risk signal: growth driven mostly by price while volumes, digital equipment, or smaller-practice demand weaken.
Margin is likely the most market-sensitive KPI. Q1’s distribution gross margin improved on better pricing execution, higher corporate-brand mix, supplier economics, and early benefits from gross-profit initiatives. Management indicated that the Q1 improvement was not solely a one-time event and expected benefits to build over the year. (investor.henryschein.com)
For Q2, investors should focus on:
The bull case is that HSIC is moving from episodic restructuring to a more durable commercial and procurement playbook: better value pricing, increased owned-brand penetration, procurement savings, and simplified operations. The bear case is that a competitive distribution market limits price capture just as freight, tariff, and input costs rise.
Medical was the weak point in Q1 because respiratory diagnostic products—roughly 15%–20% of the medical business, according to management—declined with a light flu season. Excluding that category, management said medical would have grown in the mid-single digits, supported by Home Solutions and dialysis.
That makes Q2 a useful read on the underlying medical run rate. Investors should look for mid-single-digit growth excluding respiratory testing, and for commentary on office-based utilization, reimbursement exposure, and alternate-site-of-care demand. A renewed deceleration outside of diagnostics would undermine the argument that Q1 was merely a seasonal-testing issue.
Specialty was the least convincing piece of Q1. Value implants grew at a high-single-digit rate, but premium implants were flat to lower, especially in the United States. The value mix is strategically attractive for growth, but it carries lower gross margins and therefore creates a trade-off between sales acceleration and near-term profitability.
The key questions are:
A specialty recovery would strengthen the narrative that HSIC’s higher-growth, higher-margin businesses can become a larger share of earnings over time. Continued softness would keep the focus on distribution margin improvement rather than organic specialty-led growth.
Technology grew 6.9% internally in Q1, with cloud-based customer counts up roughly 25% year over year and more than 13,000 Dentrix Ascend and Dentally subscribers. Management is also positioning AI-enabled workflow solutions as a longer-term growth opportunity. (investor.henryschein.com)
Technology is still small relative to distribution, but it is disproportionately important to the long-term mix story because of its higher gross margins, recurring characteristics, and ability to deepen customer relationships. Q2 investors should watch for continued high-single-digit organic growth, subscriber additions, AI product adoption, and signs that technology is improving customer retention or cross-selling in dental.
HSIC reaffirmed 2026 guidance in Q1 for:
After Q1’s $1.32 of non-GAAP EPS, the company needs roughly $3.91–$4.05 across Q2–Q4 to deliver its full-year range. That is achievable, but it requires the expected second-half acceleration in savings and margin expansion. Management has explicitly said value-creation benefits should be more heavily weighted to H2, targeting a $125 million annualized run rate by year-end 2026 and more than $200 million of annual operating-income improvement over the next few years. (investor.henryschein.com)
Accordingly, an unchanged guide alone may not be enough for a strong reaction if Q2 earnings are merely in line. The market will likely care more about whether management can quantify:
On July 30, HSIC announced a new leadership structure, including integration of global supply chain with global distribution and the transition of the COO, Chief Strategy Officer, and global supply-chain leader into senior-advisor roles effective at the end of October. The changes are consistent with CEO Fred Lowery’s emphasis on faster decisions, a simpler operating model, and operational accountability.
This should be viewed as strategically aligned with the value-creation agenda, but it also raises near-term questions around organizational continuity and execution. Investors should listen for details on who owns distribution, supply-chain, procurement, pricing, and transformation milestones under the new structure.
HSIC closed at $86.53 on August 3, up approximately 2.4% from July 1. The stock is also about 11.5% above the $77.64 average price at which HSIC repurchased shares in Q1.
That setup suggests investors are not treating the quarter as a distressed reset. A favorable reaction likely requires validation that Q1’s margin improvement was sustainable and that the H2 savings ramp is tangible; a guide reiteration paired with weak dental, specialty, or margin commentary could be insufficient.
The Q2 debate is about proof of execution. HSIC has a credible path to better earnings growth through dental share gains, technology growth, corporate-brand mix, pricing discipline, procurement benefits, and organizational simplification. Q1 established that this framework can work. Q2 needs to show that it is working across a broader set of businesses and is not dependent on favorable mix, FX, or one-time gains.